Kyverna Therapeutics: The King Of The CAR-T Autoimmune Revolution

Joseph Minton1 FollowerFollow5ShareSavePlay(18min)CommentsSummaryKyverna Therapeutics leads CAR-T therapy for autoimmune diseases, with KYV-101 showing unprecedented efficacy in SPS and MG registrational trials.KYTX's SPS trial achieved 81% clinically meaningful improvement and all secondary endpoints, positioning the company for a BLA filing in 1H 2026.With a $279M cash runway into 2028 and strong institutional backing, KYTX is de-risked from near-term dilution and aligns with top-tier biotech investors.I view KYTX as a long-term buy, with a TAM exceeding $80B, a seasoned ex-Kite leadership team, and a current valuation well below blue-sky potential.Editor's note: Seeking Alpha is proud to welcome Joseph Minton as a new contributing analyst. You can become one too! Share your best investment idea by submitting your article for review to our editors. Get published, earn money, and unlock exclusive SA Premium access. This article was written byJoseph Minton1 FollowerFollowHello, my name is Joseph "Kade" Minton, I prefer to go by Kade, and I enjoy writing, researching, and investing in speculative growth stocks that I think are undervalued or simply misunderstood. In particular, I think the biotech sector is on the cusp of a golden era with revolutionary breakthroughs across the board. Maybe it is a crazy idea, but I think we will witness all sorts of diseases cured or effectively treated within our near future, including things like cancer, Alzheimer's, and a swath of autoimmune disorders. Likewise, tech is progressing at a supersonic pace. I imagine things like fusion energy, solid-state batteries, and nanomaterials will be prevalent sooner than later. As for my background, I studied engineering physics and applied mathematics, and now I work in environmental and industrial compliance. From my experience, my love for numbers and regulatory knowledge has only grown into how I research stocks. My quantitative models employ heavy math concepts like differential equations and linear algebra, but I also try to balance these models with macro winds such as historical regulatory precedent. My goal in writing for Seeking Alpha is to simply share my findings in a readable format, mainly to help flesh out ideas and interact with the community of investors that reads articles from Seeking Alpha.Analyst’s Disclosure: I/we have a beneficial long position in the shares of KYTX either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.